Given that aberrant activation of mTORC1 likely triggers TSC tumor formation [1, 4], it has been suggested that rapamycin and its analogues could potentially be effective for the treatment of TSC and related cancers [8, 30, 31]. The gene discussed is TSC1; the disease is tuberous sclerosis.